GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by GSK Plc on November 24, 2022, covering the month of November 2022. The filing serves as a report of a foreign private issuer under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate announcement regarding dividend schedules rather than a financial results report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely announces the provisional dividend dates for the 2023 fiscal year.
Guidance, Outlook, and Management Commentary
Management has announced the following provisional dividend dates for 2023. These dates are indicative and may be subject to change:
- Q1 2023: Ex-dividend May 18, 2023; Payable July 13, 2023.
- Q2 2023: Ex-dividend August 17, 2023; Payable October 12, 2023.
- Q3 2023: Ex-dividend November 16, 2023; Payable January 11, 2024.
- Q4 2023 (Final): Ex-dividend February 22, 2024; Payable April 11, 2024.
Investor Verification Checklist
- Verify the final dividend amounts per share, as this filing only provides dates.
- Confirm if the indicative dates listed above remain unchanged prior to the ex-dividend dates.
- Review the upcoming Q4 2022 and Full Year 2022 earnings releases for actual financial performance metrics.